Novo Nordisk partners with OpenAI to speed drug development

Novo Nordisk (NVO) announced a strategic partnership with OpenAI that it says will place Novo Nordisk at the forefront of AI transformation in healthcare and help the company bring new and better treatment options to patients faster. The partnership will apply advanced AI capabilities to analyze complex datasets, identify promising drug candidates, and reduce the time required to move from research to patient. It has been structured with strict data protection, governance and human oversight to ensure ethical and compliant use. “This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare. There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives,” said Mike Doustdar, president and CEO of Novo Nordisk. “Integrating AI in our everyday work gives us the ability to analyze datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever. This means discovering new therapies and bringing them to market faster than ever before.” OpenAI will assist Novo Nordisk in upskilling the company’s global workforce and enhancing AI literacy. The partnership will also apply OpenAI’s capabilities to improve efficiency in manufacturing, supply chain and distribution and corporate operations. Pilot programs will launch across research & development, manufacturing and commercial operations, with full integration by the end of 2026.